link
To ask the Scottish Government what its response is to new research that shows there to be “no good evidence” that the Tamiflu vaccine reduces flu-related hospital admissions or the complications of influenza. (S4O-03149)
Official Report · Chamber
Portfolio Question Time Health and Wellbeing
link
To ask the Scottish Government what its response is to new research that shows there to be “no good evidence” that the Tamiflu vaccine reduces flu-related hospital admissions or the complications of influenza. (S4O-03149)
Tamiflu is not a vaccine. It is an antiviral medicine for the treatment and post-exposure prevention of influenza. We will consider all new relevant scientific evidence. That will include the Cochrane collaboration reviews that were published on 9 April, which considered data from the initial trials of Tamiflu and another antiviral medicine, Relenza, dating back to the late 1990s. It will also include evidence from other studies that have been carried out since the medicines were licensed, which support the view that we can help to ensure that we are providing the right approach in this area of policy and that we are using antiviral medication that can help to reduce the risks to individuals.
link
How much money was spent by the Scottish Government on stockpiling Tamiflu? If, as the minister seems to be indicating, there is to be a review of the future use of the drug, can he tell us when details of that review will be made available to the public?
I can inform the member that we intend to work with other nations in the United Kingdom to review the stockpiling of the antiviral medications Tamiflu and Relenza, in order to evaluate whether that is the most appropriate approach to take in the future.
It is worth bearing in mind that the approach that we have taken in Scotland is consistent with the guidance that was issued by the World Health Organization and the approach that has been taken by other European and north American countries around stockpiling for a pandemic flu. It dates back to the approach that was set out in 2005 on the state of preparedness that the country should be in given the potential for a pandemic flu—at that time, the concern was bird flu.
The review will be carried out over the coming months and we expect it to report by the end of this year. We wish it to report on that timescale because there are some elements of the antiviral stockpile that are due for replacement next year and it would be helpful, from our perspective, for the review to be completed by that point, in order to inform that process.
On the member’s second point, we stockpile a level of antiviral medicines that is sufficient to cover 50 per cent of the population. Some 35 per cent of that is Tamiflu and 15 per cent is Relenza. The total market cost of stockpiling Tamiflu is £21.1 million. The cost of stockpiling Relenza is £12.9 million.
I welcome the minister’s considered reply in view of the fact that I recommended to the Health and Sport Committee that it should recommend to the Government the stockpiling of Tamiflu, a position for which, at the time, the evidence was strong. Will the minister now get his Government to throw its weight behind the campaign to require the pharmaceutical industry to publish all its research prior to licensing? Hitherto in this case, partial research was published, which led to Tamiflu being thought to be of huge value.
I fully agree with the member that it is in the interests of the pharmaceutical industry to be extremely open and transparent about the evidence that it has at the time that it seeks a licence for any type of vaccination or medication. I would be more than happy to offer my support to the member’s call for the pharmaceutical industry to be as transparent as it is possible for it to be.
It is worth keeping in mind that some elements of research were not included in the Cochrane collaboration reviews, particularly observational studies that were undertaken and which will also have to form part of the review that will take place this year. The process gives us an opportunity to take time out to evaluate the types of medication that we are stockpiling in order to assess whether we are doing so in the most effective way and, if we are not, what other options might be available to us, and to consider how we can take that forward in the years to come.
The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.